Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-\(\gamma\)/Adiponectin Signalling

Alexios S. Antonopoulos,\(^*\) Marios Margaritis,\(^*\) Sander Verheule, Alice Recalde, Fabio Sanna, Laura Herdman, Costas Psarros, Hussein Nasrallah, Patricia Coutinho, Ioannis Akoumianakis, Alison C. Brewer, Rana Sayeed, George Krasopoulos, Mario Petrou, Akansha Tarun, Dimitris Tousoulis, Ajay M. Shah, Barbara Casadei, Keith M. Channon, Charalambos Antoniades

*Rationale: Adiponectin has anti-inflammatory effects in experimental models, but its role in the regulation of myocardial redox state in humans is unknown. Although adiponectin is released from epicardial adipose tissue (EpAT), it is unclear whether it exerts any paracrine effects on the human myocardium.

Objective: To explore the cross talk between EpAT-derived adiponectin and myocardial redox state in the human heart.

Methods and Results: EpAT and atrial myocardium were obtained from 306 patients undergoing coronary artery bypass grafting. Functional genetic polymorphisms that increase ADIPOQ expression (encoding adiponectin) led to reduced myocardial nicotinamide adenine dinucleotide phosphate oxidase–derived \(\text{O}_2^-\), whereas circulating adiponectin and ADIPOQ expression in EpAT were associated with elevated myocardial \(\text{O}_2^-\). In human atrial tissue, we demonstrated that adiponectin suppresses myocardial nicotinamide adenine dinucleotide phosphate oxidase activity, by preventing AMP kinase–mediated translocation of Rac1 and p47phox from the cytosol to the membranes. Induction of \(\text{O}_2^-\) production in H9C2 cardiac myocytes led to the release of a transferable factor able to induce peroxisome proliferator-activated receptor-\(\gamma\)–mediated upregulation of ADIPOQ expression in cocultured EpAT. Using a NOX2 transgenic mouse and a pig model of rapid atrial pacing, we found that oxidation products (such as 4-hydroxynonenal) released from the heart trigger peroxisome proliferator-activated receptor-\(\gamma\)–mediated upregulation of ADIPOQ in EpAT.

Conclusions: We demonstrate for the first time in humans that adiponectin directly decreases myocardial nicotinamide adenine dinucleotide phosphate oxidase activity via endocrine or paracrine effects. Adiponectin expression in EpAT is controlled by paracrine effects of oxidation products released from the heart. These effects constitute a novel defense mechanism of the heart against myocardial oxidative stress. (Circ Res. 2016;118:842-855. DOI: 10.1161/CIRCRESAHA.115.307856.)

Key Words: adiponectin \(\rightarrow\) adipose tissue \(\rightarrow\) myocardium \(\rightarrow\) obesity \(\rightarrow\) oxidative stress

Dysregulation of myocardial redox signaling is involved in the pathophysiology of multiple cardiac diseases.\(^1\) Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases are major enzymatic sources of reactive oxygen species in the heart\(^2\) and have been linked in the past to cardiac pathologies such as atrial fibrillation,\(^3,5\) myocardial hypertrophy,\(^4\) heart failure,\(^7\) and others.\(^8\) Metabolic abnormalities such as obesity or diabetes mellitus are associated with increased NADPH oxidases activity in the cardiovascular system\(^9,8\) although the underlying mechanisms of these links are controversial.\(^10,11\) Because pharmacological treatments able to suppress myocardial NADPH oxidases (eg, statins as a part of their pleiotropic effects in the human heart\(^9\)) have failed to prevent cardiac disease progression in humans,\(^12\)
Adiponectin is an important adipokine with anti-inflammatory activity of the neighboring EpAT. Myocardial oxidative stress, which controls the biosynthetic/adiponectin signaling in human EpAT, and receptor (PPAR)-the mechanisms controlling peroxisome proliferator-activated adiponectin's effects on the heart. In addition, EpAT from the atrioventricular groove and thoracic adipose tissue (ThAT) from the outer surface of the pericardium were collected and used to quantify the expression of ADIPOQ and adiponectin receptors. In addition, EpAT is an important adipokine with anti-inflammatory and antioxidant effects on the vasculature and the heart of experimental models, but its role in the regulation of myocardial redox state in humans is unknown.

In healthy individuals, low circulating adiponectin is associated with increased cardiovascular risk; however, in individuals with ischemic heart disease (IHD), adiponectin gene expression in adipose tissue is increased and high circulating adiponectin predicts adverse clinical outcome. Importantly, given that the human heart is surrounded by biologically active epicardial adipose tissue (EpAT), adiponectin released from it may exert additional paracrine effects on the underlying myocardium in a similar way perivascular adipose tissue exerts paracrine effects on the vascular wall, a concept that has not been previously explored.

In this study, we explore the role of adiponectin in the regulation of myocardial redox state in patients with IHD, and we characterize the underlying molecular mechanisms mediating adiponectin's effects on the heart. In addition, we define the mechanisms controlling peroxisome proliferator-activated receptor (PPAR)-γ/adiponectin signaling in human EpAT, and we introduce the novel concept of an inside to outside signaling released from the human heart in conditions of increased myocardial oxidative stress, which controls the biosynthetic activity of the neighboring EpAT.

**Methods**

**Study Population**

The study population consisted of 306 patients undergoing coronary artery bypass grafting; 247 of these were included in the Clinical Associations Studies and 59 into the ex vivo arm of the study. Blood samples were obtained on the morning of surgery, whereas samples of myocardium and adipose tissue were collected during surgery, as described below. Myocardial and adipose tissue samples were used for ex vivo experiments to address the mechanisms regulating the cross talk between EpAT and human myocardium as described below. Exclusion criteria were any inflammatory, infectious, liver or renal disease, or malignancy. Patients receiving nonsteroidal anti-inflammatory drugs, dietary supplements, or antioxidant vitamins were also excluded.

**Design of the Clinical Associations Studies**

In 247 patients undergoing coronary artery bypass grafting, blood samples were collected at the morning of surgery for measuring circulating adiponectin and other biomarkers as well as for DNA extraction and genotyping. Samples of right atrial appendage obtained from the cannulation site were used to quantify NADPH oxidase-derived superoxide anions (O2−), aiming to relate it with circulating adiponectin and the expression of ADIPOQ gene (encoding adiponectin) in different adipose tissue depots. These myocardial samples were also used to study the myocardial expression of ADIPOQ and adiponectin receptors. In addition, EpAT from the atrioventricular groove and thoracic adipose tissue (ThAT) from the outer surface of the pericardium were collected and used to quantify the expression of ADIPOQ and other target genes, aiming to search for predictors of myocardial redox state as described below. More detail on samples collection and processing is provided in the Online Data Supplement.

**Blood Sampling and Measurement of Circulating Biomarkers**

Venous blood samples were obtained after 8 hours of fasting, on the morning of the operation, and used for measurement of circulating biomarkers (as described in the Online Data Supplement).

**DNA Extraction and Genotyping**

Genomic DNA extraction from whole blood and genotyping were performed using standard methods (as described in the Online Data Supplement).

**Myocardial Superoxide Measurements**

Myocardial O2− production was measured in right atrial appendage samples using lucigenin (5 μmol/L)-enhanced chemiluminescence (as described in the Online Data Supplement).

**RNA Isolation and Quantitative Real-Time-Polymerase Chain Reaction**

Samples of adipose tissue and right atrial appendage were used for RNA extraction and gene expression studies (as described in the Online Data Supplement).

**Ex Vivo Experiments With Human Myocardium**

To examine the direct effects of adiponectin on myocardial O2− production, human myocardial tissue from the right atrial appendage was incubated ex vivo for 2 hours with/without adiponectin in the presence/absence of the pharmacological inhibitor of AMP-kinase (AMPK), compound C (CC). Briefly, myocardial tissue was washed in ice-cold Krebs HEPES buffer, and then cut into thin strips containing all myocardial layers. The tissue was first equilibrated for 20 minutes in Krebs HEPES buffer pH 7.35 at 37°C, and then incubated for 2 hours in the presence or absence of recombinant full-length adiponectin 0.3 μmol/L (10 μg/mL; BioVendor)±CC (10 μmol/L). The effect of adiponectin on myocardial O2− (basal and NADPH-stimulated O2−) was quantified by lucigenin (5 μmol/L)-enhanced chemiluminescence (as described in the Online Data Supplement). To estimate the effect of adiponectin on NADPH oxidase-derived O2−, we used the pan-NADPH oxidase inhibitor Vas2870 (40 μmol/L; Sigma Aldrich).

**Ex Vivo Experiments With Human Adipose Tissue**

Samples of ThAT and EpAT obtained from patients in the ex vivo study arm were used to estimate the effects of lipid oxidation products on ADIPOQ gene expression in an ex vivo bioassay. Briefly, adipose tissue was isolated and washed in sterile phosphate buffer saline (PBS). The samples of adipose tissue of each type were transferred to the laboratory within 30 minutes from harvesting. The samples were then cut into 1- to 2-mm3 cubes, washed, and equilibrated for 2 hours at 37°C in Medium-199 containing HEPES (25 mmol/L), gentamicin 105 μmol/L (50 μg/mL), and fatty acid–free BSA (1%), in the presence of protease inhibitor (Roche Applied Science) in a cell culture incubator with 5% CO2 atmosphere. At the end of the equilibration period, the media was replaced by fresh media (1 mL/200 mg tissue).
and incubated for 16 hours as above but in the presence or absence of (1) H$_2$O$_2$ (100 μmol/L), (2) malondialdehyde (1 mmol/L), (3) 4-hydroxynonenal (HNE, 30 μmol/L), or (4) T0070907 (10 μmol/L, an inhibitor of PPAR-γ). For the samples treated with T0070907, this agent was also used during the equilibration period. At the end of the 16-hour incubation period, AT samples were filtered, collected, and stored at −80°C until analysis. Quantitative real-time-polymerase chain reactions were performed (as described in the Online Data Supplement) to determine ADIPOQ, PPAR-γ, and CD36 gene expression.

**Cocultures of Rat EpAT With H9C2 Cells**

To evaluate the interaction between AT and myocardium, the rat cardiac myocyte–derived cell line H9c2 was cocultivated with rat EpAT ex vivo. Briefly, H9c2 cells were differentiated to cardiac myocytes in Dulbecco’s Modified Eagle Medium (Sigma-Aldrich) supplemented with 1% horse serum (Sigma-Aldrich). The cells were exposed to either NADPH (100 μmol/L) or phorbol-12-myristate-13-acetate (PMA; 160 nmol/L) for 2 hours as a means to induce O$_2^-$ generation from NADPH oxidases. Freshly collected rat EpAT from female Wistar rats was then added to the culture medium and cocultivated with H9c2-derived cardiac myocytes with or without NADPH (100 μmol/L, n=7) or PMA 160 nmol/L (n=7) for 16 hours. To control for direct effects of NADPH or PMA on adipose tissue, EpAT was also incubated alone in the presence or absence of NADPH (100 μmol/L) or PMA (160 nmol/L). To prevent any direct effects of endogenous O$_2^-$ in EpAT, additional interventions with NADPH (100 μmol/L) and polyethylene glycol (PEG)-SOD (300 U/mL, a scavenger of O$_2^-$) or Vas2870 (10 nmol/L, an inhibitor of NADPH oxidases) were included. At the end of the incubation period, EpAT was collected for gene expression studies (as described in the Online Data Supplement).

**Measurement of Intracellular NADP/NADPH Levels**

Intracellular NADP/NADPH levels were measured using a commercially available fluorometric assay (Abcam kit, Cambridge, United Kingdom) as described in the Online Data Supplement.

**Western Blots in Human Myocardial Samples**

Western blotting was performed as described in the Online Data Supplement.

**Measurement of Myocardial Rac1 Activation and Membrane Translocation Experiments**

Rac1 activation and membrane translocation of Rac1 and p47phox were determined in right atrial appendage samples, as previously described (Online Data Supplement).

**Animal Studies**

**Mouse Model**

Cardiac myocyte–specific NOX2-transgenic mice (mNOX2-tg; Online Data Supplement) were used as a model of chronically increased myocardial oxidative stress to test the impact of increased myocardial Nox2-derived O$_2^-$ production on adiponectin expression in subcutaneous and pericardial adipose tissue (attached to the apex of the heart).

Twenty-week-old transgenic male mice and wild-type littermate controls were euthanized, and whole heart samples and samples of subcutaneous and pericardial AT were harvested and studied.

**Pig Model**

Given the limitations related to the study of pericardial AT in mice (limited amount of tissue, not always present), we used a larger mammal model (pig), whose EpAT is directly attached on the heart muscle, mimicking the interaction between myocardium and EpAT in humans. To induce a chronic increase in oxidative stress in the atrial myocardium, we used a standardized protocol of rapid atrial pacing for 4 weeks and collected EpAT from the posterior left atrium at the end of this period. Subcutaneous AT was used as a control depot. More details on the pig model are provided in the Online Data Supplement.

Myocardial tissue samples from the 2 animal models were homogenized and used for lucigenin-enhanced chemiluminescence experiments to assess myocardial NADPH oxidases activity (as described in the Online Data Supplement) and to blot for 4HNE and malondialdehyde protein adducts (antibodies by Abcam). RNA was extracted from myocardial and AT samples and used for gene expression studies (as described in the Online Data Supplement).

**Statistical Analysis**

Continuous variables were tested for normal distribution using Kolmogorov–Smirnov test. Non-normally distributed variables were log-transformed for analysis. In the Clinical Associations Study arm, continuous variables among 3 groups were compared using 1-way ANOVA followed by the Bonferroni post hoc test for individual comparisons, whereas comparisons between 2 groups were performed by unpaired $t$ tests. Categorical variables were compared using the $\chi^2$ test as appropriate. Correlations between continuous variables were assessed by bivariate analysis, and the Pearson coefficient was estimated.

For the ex vivo experiments (in which serial segments from the same right atrial appendage were incubated with multiple interventions), we performed repeated-measures ANOVA and paired $t$ tests for individual comparisons, followed by the Bonferroni post hoc correction for multiple testing as appropriate. In the Clinical Associations study arm, correlations between continuous variables were tested by calculating the Pearson correlation coefficient. Multivariable linear regression was performed by using log(NADPH-stimulated O$_2^-$) or log(serum adiponectin) as dependent variables and by using demographic/biological variables that showed a significant association with the dependent variable in univariate analysis at the level of 15% as independent variables.

For the animal studies, comparisons of mNOX2-tg versus wild-type mice or rapid atrial pacing versus sham were performed using unpaired $t$ test of the log-transformed values for the respective variables. Power calculations are provided in the Online Data Supplement. All statistical tests were performed with SPSS version 20.0, and values of $P<0.05$ were considered statistically significant.

**Results**

**Interactions Between Adiponectin and Myocardial NADPH Oxidases Activity in Patients With IHD**

The characteristics of the patients included in the Clinical Associations Studies are presented in the Table. In this cohort of patients with IHD, we first explored the association between adiponectin levels and myocardial redox state. We observed a positive association between circulating adiponectin and myocardial NADPH-stimulated O$_2^-$ (Figure 1A), as well as between circulating adiponectin and malondialdehyde (Figure 1B), a plasma marker of oxidative stress. However, there was no significant association between adiponectin and either interleukin-6 (Figure 1C) or high-sensitivity C-reactive protein (Figure 1D), suggesting that systemic inflammation does not confound the association between circulating adiponectin and myocardial NADPH oxidases activity. We also observed a significant association between plasma brain natriuretic peptide (BNP) and circulating adiponectin (Figure 1E), but not between BNP and NADPH-stimulated O$_2^-$ in the myocardium (Online Table I) or plasma malondialdehyde ($r=0.147; P=0.092$). To further explore the association between myocardial redox state and serum adiponectin, we performed univariate analysis followed by multivariable analysis searching for predictors of myocardial NADPH oxidases-derived O$_2^-$ (Online Table
Table. Demographic Characteristics of Study Participants

<table>
<thead>
<tr>
<th>Clinical Associations Studies</th>
<th>Ex Vivo Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants (n)</td>
<td>247</td>
</tr>
<tr>
<td>Age, y</td>
<td>66.8±0.6</td>
</tr>
<tr>
<td>Gender (men)</td>
<td>200</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>66.9</td>
</tr>
<tr>
<td>Dyslipidemia, %</td>
<td>49.8</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>32.5</td>
</tr>
<tr>
<td>Smoking (active/ex)</td>
<td>28.2/43.3</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.5±0.27</td>
</tr>
<tr>
<td>Cholesterol, mmol/L</td>
<td>4.34±0.2</td>
</tr>
<tr>
<td>HDL, mmol/L</td>
<td>0.94±0.04</td>
</tr>
<tr>
<td>Triglycerides, mmol/L†</td>
<td>1.39 (1.06–1.80)</td>
</tr>
<tr>
<td>Body surface area, m²</td>
<td>1.89±0.18</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>99.24±0.85</td>
</tr>
<tr>
<td>Waist:hip ratio</td>
<td>1.08±0.02</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>7.28±0.39</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>5.43±1.65</td>
</tr>
<tr>
<td>BNP, pg/mL</td>
<td>145±29</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
</tr>
<tr>
<td>ACE/ARBs</td>
<td>49.1/15.0</td>
</tr>
<tr>
<td>β-blockers</td>
<td>68.4</td>
</tr>
<tr>
<td>Aspirin/clopidogrel</td>
<td>64.4/44.2</td>
</tr>
<tr>
<td>Statins</td>
<td>66.2</td>
</tr>
<tr>
<td>CCBs</td>
<td>20.5</td>
</tr>
<tr>
<td>Diuretics</td>
<td>20.7</td>
</tr>
</tbody>
</table>

ACE/ARBs indicates angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; BMI, body mass index; BNP, brain natriuretic peptide; CCBs, calcium channel blockers; HDL, high-density lipoprotein; and HOMA-IR, homeostatic model of insulin resistance.

*P<0.05 vs population in Clinical Associations studies.
†Values expressed as median (25th–75th percentile).

I), confirming that the correlation between circulating adiponectin and myocardial NADPH oxidases activity is independent of BNP and other potential confounders (Figure 1A; Online Table I). In addition, this was independent of medication such as statins (βst=-0.314; P=0.0001), antiplatelet treatment (βst=-0.179; P=0.29), β-blockers (βst=0.013; P=0.877), calcium channel blockers (βst=-0.019; P=0.807), or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (βst=0.016; P=0.833), with R² for the model 0.238. Interestingly, serum levels of adiponectin or ADIPOQ gene expression in EpAT were not related with the incidence of postoperative atrial fibrillation (data not shown), which we have previously shown to be increased in patients with high atrial NADPH-oxidases activity.5

To further explore the association between adiponectin and myocardial redox state, we genotyped our study population for 2 functional single nucleotide polymorphisms in the ADIPOQ locus encoding adiponectin (both single nucleotide polymorphisms with known effect on adiponectin levels), located in the ADIPOQ locus (rs266717) and in the promoter region (rs17366568).24-25 We found that the number of rs266717G and rs17366568T alleles was positively associated with serum adiponectin (Figure 2A) and negatively associated with myocardial NADPH oxidases activity (Figure 2B). This implies that low adiponectin production in human AT is causally associated with higher myocardial NADPH oxidases activity. Furthermore, there was a significant effect of the single nucleotide polymorphisms on the expression of ADIPOQ gene in ThAT (Figure 2C), but this was not observed in EpAT (Figure 2D), suggesting that local mechanisms may over-ride the influence of genetic background on ADIPOQ gene expression in EpAT but not in remote adipose tissue depots such as ThAT.

We next examined whether obesity and adipose tissue distribution alter the regulation of ADIPOQ gene expression in different adipose tissue depots. We confirmed that ADIPOQ gene expression in ThAT was strongly inversely correlated with waist:hip ratio and body mass index, whereas PPAR-γ expression was similarly correlated with waist:hip ratio (although its association with body mass index was borderline significant; Online Figure IA–ID). However, these associations were not present in EpAT (Online Figure IE–IH). These discordant findings between EpAT and ThAT suggest that PPAR-γ/adiponectin signaling in EpAT is controlled by local mechanisms, possibly originating in the heart, rather than by systemic effects related to obesity and insulin resistance.

Importantly, there was a positive association between myocardial NADPH-stimulated O₂− and the expression of both ADIPOQ (Figure 2E) and PPAR-γ genes (Figure 2F) in EpAT, suggesting that increased myocardial O₂− may influence the expression of ADIPOQ in EpAT, possibly by regulating PPAR-γ expression. ADIPOQ gene expression is known to be partly under the control of PPAR-γ signaling. This was confirmed by the association between log(PPAR-γ) and log(ADIPOQ) gene expression in EpAT of patients with IHD (r=0.598; P<0.0001).

To explore whether myocardial resistance to adiponectin is responsible for the positive association between myocardial redox state and adiponectin levels (systemic and EpAT expression), we studied the expression of ADIPOQ and adiponectin receptors (ADIPOR1, ADIPOR2, and CDH13) in the myocardium of patients with advanced coronary atherosclerosis. There was no association between myocardial NADPH oxidases activity and ADIPOQ gene expression (Figure 2G), whereas there was a positive association between myocardial NADPH oxidase activity and ADIPOR1 (but not ADIPOR2 or CDH13; Figure 2H), suggesting that in the presence of increased myocardial reactive oxygen species generation, there is upregulation of ADIPOR1 in human myocardium and an upregulation of ADIPOQ gene in EpAT.

Adiponectin Directly Decreases NADPH Oxidases Activity in the Human Myocardium

To examine whether adiponectin has the ability to affect myocardial redox state in humans, myocardial tissue from patients with IHD (Table) was incubated with adiponectin (10 μg/mL) for 2 hours. Exogenous adiponectin rapidly induced phosphorylation of AMPK at the activatory site Thr172 (Figure 3A) and the downstream target acetyl-CoA carboxylase, via phosphorylation at Ser79 (Figure 3B). As expected, the observed effects on acetyl-CoA carboxylase phosphorylation, a marker of AMPK activity, were prevented by the AMPK inhibitor CC.
Similarly, adiponectin induced a rapid reduction of myocardial \( \text{O}_2^- \) production that was reversed by CC (Figure 3C). Importantly, adiponectin suppressed the Vas2870-inhibitable fraction of myocardial \( \text{O}_2^- \) in a CC-inhibitable manner (Figure 3D), suggesting that adiponectin inhibits NADPH oxidase activity via an AMPK-mediated mechanism. These AMPK-dependent effects of adiponectin were also confirmed in dihydroethidium staining experiments; adiponectin reduced both the total and the Vas2870-inhibitable dihydroethidium fluorescence (Figure 3E–3G). Adiponectin did not have any effects on the gene expression or protein levels of Nox isoforms or any NADPH oxidase subunits in human myocardium (Online Figure II), but prevented the activation of Rac1 (reduced the GTP-Rac1/total Rac1) and its membrane translocation (Figure 3H and 3I), as well as the phosphorylation of the p47phox subunit of Nox2 at its activating site Ser359 and its membrane translocation (Figure 3J and 3K). Both the effects of adiponectin on Rac1 and p47phox were reversed by CC, suggesting that these effects involved AMPK signaling. Interestingly, the AMPK-mediated effects of adiponectin on Rac1 and p47phox activation/membrane translocation were independent of any change in Akt activity, as evidenced by Western blotting for phospho-Akt at its activation site Ser473, or protein kinase C-\( \alpha \) phosphorylation status (Online Figure II).

These data suggest that adiponectin suppresses NADPH oxidases activity in the human myocardium in an AMPK-dependent mechanism. Taken together with the observed positive association between myocardial NADPH oxidases activity and \( \text{ADIPOQ} \) gene expression in EpAT (Figure 2E), these findings suggest that myocardial \( \text{O}_2^- \) production may be driving (directly or indirectly) the expression of PPAR-\( \gamma \)/\( \text{ADIPOQ} \) in EpAT.

**Identifying a Novel, Redox Sensitive Signal From Cardiac Myocytes to EpAT**

To explore the hypothesis that the release of a transferable factor from cardiac myocytes under conditions of increased oxidative stress may drive PPAR-\( \gamma \)/\( \text{ADIPOQ} \) expression in the EpAT, we exposed H9c2 cells to NADPH (100 \( \mu \text{mol/L} \), the substrate of NADPH-oxidases) for 2 hours (Figure 4A), as a means to increase the production of \( \text{O}_2^- \) from NADPH oxidases in these cells (Figure 4B and 4C). Exogenous NADPH increased intracellular NADPH by 25% (Online Figure III). The NADPH-simulated \( \text{O}_2^- \) in these cells was inhibited by \( \approx 60\% \) using pan-Nox inhibitor Vas2870 and by 50% using the specific Nox2 inhibitor gp91-dstat (Figure 4). At the end of the 2-hour incubation period with NADPH, we cocultured freshly collected rat EpAT with the stimulated H9c2 cells for 16 hours (Figure 4A). At the end of the incubation
period, we measured gene expression in the EpAT from coculture. There was no change in the expression of ADIPOQ, PPAR-γ, or CD36 genes in rat EpAT incubated with NADPH alone or cocultured with H9c2 cells without added NADPH (Figure 4D–4F). However, coculture of rat EpAT with H9c2 cells prestimulated with NADPH resulted in a significant increase in ADIPOQ gene expression (Figure 4D) as well as expression of PPAR-γ (Figure 4E) and its downstream target CD36 (Figure 4F). These effects were all prevented by the O₂⁻ scavenger PEG-SOD or the NADPH oxidases inhibitor Vas2870 (Figure 4D–4F). These findings indicate that increased O₂⁻ production from H9c2 cells leads (either directly or indirectly via an intermediate factor) to upregulation of PPAR-γ/adiponectin expression in rat EpAT.

Figure 2. Genetically conferred increases in adiponectin (AdN) bioavailability are causally associated with lower nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in the human myocardium. The total number of rs17366568G alleles (polymorphism in ADIPOQ gene) and rs266717T alleles (polymorphism in ADIPOQ gene promoter) had an additive effect on circulating AdN levels (A) and was associated with reduced NADPH–stimulated superoxide (O₂⁻) in human myocardium (B). The number of rs17366568G/rs266717T alleles was positively associated with higher ADIPOQ gene expression in thoracic adipose tissue (ThAT, C), but not associated in epicardial adipose tissue (EpAT; D). Patients with higher ADIPOQ (E) or peroxisome proliferator-activated receptor (PPAR)-γ (F) gene expression in EpAT also had higher NADPH-stimulated O₂⁻ production in their myocardium. Higher myocardial NADPH-stimulated O₂⁻ was not associated with endogenous ADIPOQ gene expression in the heart (G), but was associated with higher gene expression of adiponectin receptor-1 (AdipoR1), but not of AdipoR2 or T-cadherin (CDH13) in human myocardial tissue (H). Values are expressed as median (25th–75th percentile). RLU indicates relative light units.
As an alternative model to stimulate \( \text{O}_2^- \) generation in H9C2 cells in the above experiment, we repeated the same experimental design by using PMA 160 nmol/L instead of NADPH (Online Figure IV). We observed a similar upregulation of \( \text{ADIPOQ} \) and \( \text{PPAR-\gamma} \) in rat EpAT that was inhibitable by Vas2870. However, the same effect was also observed in the absence of H9C2 cells, suggesting a direct effect of PMA on \( \text{PPAR-\gamma} \) signaling in the EpAT (Online Figure IV).

**Myocardial Oxidation Products as Candidate Mediators of Inside-To-Outside Cardiac-Adipose Tissue Signaling.**

Because \( \text{O}_2^- \) is a short-lived, highly reactive molecule, we hypothesized that other longer-lived reactive oxygen species rather than \( \text{O}_2^- \) itself (eg, \( \text{H}_2\text{O}_2 \)) or even products of lipid oxidation could act as transferable factors released from cardiac myocytes under oxidative stress conditions to exert a paracrine effect on EpAT. Incubation of human EpAT with \( \text{H}_2\text{O}_2 \) (100 \( \mu \text{mol/L} \)) suppressed \( \text{ADIPOQ} \) gene expression (Online Figure VIA), suggesting that direct exposure of EpAT to \( \text{H}_2\text{O}_2 \) cannot explain the observation in the Clinical Associations Studies that high myocardial oxidative stress is linked to high \( \text{ADIPOQ} \) expression in EpAT (Figure 2E).

Next, we examined whether products of lipid oxidation (formed under conditions of high myocardial oxidative stress) could modulate \( \text{ADIPOQ} \) expression in EpAT. We found that increased activity of NADPH oxidases in the human myocardium leads to increased formation of common oxidation products, such as 4HNE and malonyldialdehyde, which form detectable adducts with proteins in the human myocardium (Figure 5A and 5B). 4HNE adducts are also rapidly increased in human myocardial tissue after ex vivo exposure to NADPH (100 \( \mu \text{mol/L} \); Online Figure V). Incubation of human EpAT and ThAT with malonyldialdehyde had no impact on \( \text{ADIPOQ} \) (Figure 5C), \( \text{PPAR-\gamma} \), or \( \text{CD36} \) gene expression (Online Figure...
VII) in either adipose tissue depot. By contrast, exposure of human EpAT to 4HNE induced a rapid 7-fold upregulation of ADIPOQ gene expression, an effect that was prevented by the PPAR-γ activity inhibitor T0070907 (Figure 5D). 4HNE also induced a respective 2-fold upregulation of PPAR-γ gene expression (Figure 5E) and a 5-fold increase of its downstream gene, CD36 (Figure 5F), the latter being prevented by the use of T0070907 (Figure 5F). Interestingly, the expression of PPAR-γ was significantly higher in EpAT than in ThAT, further supporting the notion that its expression in EpAT is largely driven by local signals released from the human myocardium (Online Figure VIII). Taken together, these findings suggest that 4HNE exerts its effects on ADIPOQ gene expression not only by upregulating PPAR-γ but also by enhancing its downstream signaling (Figure 5E and 5F). Interestingly, 4HNE had no effect on the expression of ADIPOQ, PPAR-γ, and CD36 genes in remote sites of adipose tissue such as ThAT (Figure 5G–5I), supporting the hypothesis that 4HNE released from the human heart under conditions of increased oxidative stress may activate PPAR-γ signaling in EpAT via a paracrine mechanism.

Testing the Paracrine Effects of the Heart on EpAT Using Animal Models

To further explore whether a selective increase in myocardial NADPH oxidases activity would lead to upregulation of ADIPOQ gene expression in EpAT in vivo, we used a transgenic mouse model with cardiac myocyte–specific
overexpression of human NOX2 (mNOX2-Tg; Online Figure IX) given the strong association of the latter with myocardial redox state in humans (Online Figure X). Subcutaneous and pericardial AT was collected from 20-week old male mNOX2-Tg and wild-type littermate mice. Overexpression of NOX2 in the myocardium of these mice (demonstrated in Online Figure IX) resulted in a significant increase of NADPH oxidases activity, as assessed by both the NADPH-stimulated $O_2^-$ (Figure 6A) and Vas2870-inhibitable $O_2^-$ production (Figure 6B). Overexpression of NOX2 also led to increased formation of 4HNE—but not of malonyldialdehyde—adducts in the myocardium of mNOX2-Tg mice (Figure 6C and 6D). Interestingly, there was a striking upregulation of ADIPOQ expression in pericardial but not in subcutaneous AT of the mNOX2-tg mice (Figure 6E). Myocardial NOX2 overexpression also led to increased ADIPOQ gene expression in the myocardium (Figure 6F), but did not affect the expression of adiponectin receptors in the myocardium (Figure 6G).

Figure 5. Myocardial oxidation product 4-hydroxynonenal (4HNE) as a mediator of the inside-to-outside signal from the human myocardium to epicardial adipose tissue (EpAT). In human myocardium, increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidases activity (upper tertile of NADPH-stimulated $O_2^-$ in the Clinical Associations Studies) were associated with significantly greater 4HNE (A) and malonyldialdehyde (MDA; B) production. Incubation of EpAT and thoracic (ThAT) adipose tissue with MDA (1 mmol/L) for 16 h had no significant impact on ADIPOQ gene expression (C). On the contrary, incubation of EpAT with 4HNE (30 µmol/L) for 16 h induced a striking increase in ADIPOQ (D), PPAR-γ (E) and CD36 (F). The effects of 4HNE on ADIPOQ and CD36 gene expression were reversed by the inhibitor of PPAR-γ activity, T0070907 (10 µmol/L; D and F). Importantly, 4HNE had no significant impact on the expression of ADIPOQ (G), PPAR-γ (H), or CD36 (I) genes in ThAT. Values are represented as fold change compared to control group (meansSEM). A and B, n=4 per group; C) n=5 per group; (D–I), n=5 to 8 per group, *P<0.05; **P<0.01 vs low myocardial NADPH oxidase activity (A and B) or control (C to I).
To test whether the findings from the mNOX2-tg mouse model could be replicated in a large animal, with typical EpAT distribution closer to the human one, we used rapid atrial pacing in the pig to increase myocardial O$_2^-$ production. As we have previously shown, rapid atrial pacing increases myocardial NADPH oxidase activity in the left atrium as assessed by both the NADPH-stimulated O$_2^-$ and the Vas2870-inhibitable O$_2^-$ signal (Figure 7A and 7B). Activation of atrial NADPH oxidase resulted in increased myocardial formation of 4HNE but not of malonyldialdehyde adducts (Figure 7C and 7D, respectively) and led to a striking upregulation of ADIPOQ expression in EpAT attached to the left atrium, whereas there was no significant effect on ADIPOQ expression in subcutaneous adipose tissue (Figure 7E), or on the expression of endogenous adiponectin (Figure 7F) or adiponectin receptors (Figure 7G) in the left atrium. Taken together, these data demonstrate that increased NADPH oxidase activity in the heart leads to upregulation of ADIPOQ expression specifically in EpAT. This corroborates the findings from our cell culture and ex vivo work in human atrial tissue and explains the positive associations between ADIPOQ expression in EpAT and NADPH oxidase activity in the underlying myocardium of patients with IHD.

**Discussion**

In the present study, we explore for the first time in humans, the role of adipose tissue-derived adiponectin in the regulation of myocardial redox state, through modulation of NADPH oxidase activity. Adiponectin prevents the phosphorylation and membrane translocation of p47phox and prevents Rac1 activation and membrane translocation, both key aspects of myocardial NADPH oxidase activation. Under conditions of increased myocardial O$_2^-$ generation, oxidation products such as 4HNE can act as signaling molecules from the heart, to activate adiponectin release from EpAT in a PPAR-$\gamma$-dependent manner. This introduces the novel concept that, through the release of oxidation products, the human heart regulates key biological processes in adipose tissue by triggering rescue PPAR-$\gamma$ signaling leading to increased release of adiponectin, which then exerts cardioprotective effects. This novel inside-to-outside

![Figure 6. Testing the inside-to-outside paracrine effects of the heart on pericardial adipose tissue using a cardiomyocyte-specific Nox2-tg mouse model.](http://circres.ahajournals.org/doi/10.1161/CIRCRESAHA.116.310052)
signal may be a therapeutic target for the prevention and treatment of redox-dependent cardiac diseases.

Myocardial redox state is a critical determinant of cardiac biology by modulating the function of ion channels, sarcoplasmic reticulum calcium release channels, and myofilament proteins, in cardiac myocytes. Oxygen radical species such as superoxide anion \( \text{O}_2^- \) causes damage to cell membranes and leads to cardiac myocyte necrosis and apoptosis, whereas redox-sensitive signaling pathways control fibrotic and hypertrophic responses. NADPH oxidases and particularly Nox2 are major contributors to \( \text{O}_2^- \) production in the cardiovascular system, leading to the development of multiple cardiac pathologies such as heart failure, myocardial hypertrophy, atrial fibrillation, and others. Nox2 activation is dependent on Rac1 binding with GTP as well as p47phox phosphorylation and their subsequent translocation to the membrane to form the active catalytic complex of the enzyme. In this study, we demonstrate that systemic oxidative stress (as characterized by plasma malonyldialdehyde) is not significantly correlated with NADPH oxidase activity in human myocardium, confirming our previous observation that myocardial redox state is independent of markers of systemic oxidative stress and may be subjected to local, largely unknown regulatory mechanisms.

Human adipose tissue secretes a wide range of adipocytokines able to affect myocardial biology. In addition, EpAT has been proposed to exert paracrine effects on the underlying epicardial coronaries. Given the close anatomic relationship between myocardium and EpAT in humans (with adipose tissue penetrating into the heart muscle), it seems that EpAT exerts paracrine effects on the underlying myocardium affecting its biology, as recently demonstrated in some elegant translational studies by Greulich et al. Adiponectin seems to have some direct effects on myocardial redox state in animal and cell culture models, but its role in the regulation of redox state in the human heart is unknown. It is also unclear whether adiponectin produced in EpAT has any paracrine role in the regulation of myocardial redox state, as suggested above.

In this study, we first evaluated the association between myocardial NADPH oxidases activity and circulating adiponectin or the expression of adiponectin from EpAT or ThAT.
in a cohort of patients with IHD. Paradoxically, we observed a positive association between myocardial NADPH-stimulated O$_2^-$ and circulating adiponectin as well as $ADIPQ$ gene expression in EpAT. A similar positive association was also observed between myocardial NADPH-stimulated O$_2^-$ and adiponectin receptor AdipoR1. As this was the first study exploring the role of adiponectin in the regulation of myocardial redox state in humans, we then tried to explore the direction of that unexpected association. By taking advantage of the genetic variability of $ADIPQ$ gene described in recent genome-wide association studies, we observed that genetically determined reduction of adiponectin levels is also associated with increased NADPH-stimulated O$_2^-$ in the heart of patients with IHD (an association independent of other covariates, including BNP), implying that low adiponectin production in the human AT is causally associated with higher myocardial NADPH oxidase activity. Using an ex vivo model of human myocardium, we observed that adiponectin had a direct inhibitory effect on myocardial NADPH oxidase activity (evidenced by a reduction in Vas2870-inhibitable myocardial O$_2^-$) and that this effect is mediated by the activation of AMPK leading to reduced phosphorylation and membrane translocation of NADPH oxidase subunit p47phox in parallel to an AMPK-mediated suppression of Rac1 activation and membrane translocation. This is the first study defining the molecular mechanisms by which adiponectin suppresses NADPH oxidase activity in the human heart, but these findings are still unable to explain the positive association observed between myocardial redox state and $ADIPQ$ gene expression in EpAT in patients with IHD.

In advanced cardiovascular disease states (ie, heart failure), circulating adiponectin is significantly elevated. In cell culture studies, it was demonstrated that adipocytes respond to exogenous BNP (which is significantly elevated in heart failure) by upregulating $ADIPQ$ gene expression, and we have recently demonstrated that this stimulatory effect of BNP on human adipose tissue over-rides the suppressive effect of inflammation on the expression and release of adiponectin. Although BNP seems to drive the circulating adiponectin level in the presence of heart failure, its role in the regulation of adipose tissue biology in the absence of heart failure seems less important. In this study, we demonstrate that both circulating adiponectin and $ADIPQ$ gene expression in EpAT are positively correlated with myocardial oxidative stress. Therefore, the exact mechanism by which exogenous adiponectin inhibits NADPH oxidase in the human myocardium via an AMPK/Rac1/p47phox-mediated signaling, which is unlikely to cross the plasma membranes by simple diffusion, is still unknown.

Sources of Funding
This work was supported by a Marie Curie Intra European Fellowship by European Commission within the 7th Framework Programme
Disclosures

None.

References

What Is Known?

- Nicotinamide adenine dinucleotide phosphate oxidases are major contributors to myocardial oxidative stress in humans.
- Epicardial adipose tissue is an endocrine tissue that secretes active adipokines.
- In experimental animal models, adipose tissue–derived adiponectin has beneficial effects on cardiovascular system.

What New Information Does This Article Contribute?

- Adiponectin suppresses oxidative stress in the human heart.
- A novel inside-to-outside signal from the heart to it epicardial adipose tissue is described, introducing the concept of a cross talk between the human heart and its epicardial adipose tissue.
- Increased myocardial oxidative stress induces changes in the biology of the adjacent epicardial adipose tissue in humans, triggering local adiponectin expression in epicardial fat.
- Modulations of adiponectin production by the epicardial adipose tissue can be considered as a local defense mechanism to protect the heart from oxidative injury.
Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-γ/Adiponectin Signalling

Alexios S. Antonopoulos, Marios Margaritis, Sander Verheule, Alice Recalde, Fabio Sanna, Laura Herdman, Costas Psarros, Hussein Nasrallah, Patricia Coutinho, Ioannis Akoumianakis, Alison C. Brewer, Rana Sayeed, George Krasopoulos, Mario Petrou, Akansha Tarun, Dimitris Tousoulis, Ajay M. Shah, Barbara Casadei, Keith M. Channon and Charalambos Antoniades

Circ Res. 2016;118:842-855; originally published online January 21, 2016;
doi: 10.1161/CIRCRESAHA.115.307856

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/118/5/842
Free via Open Access

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2016/01/21/CIRCRESAHA.115.307856.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL

Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-\(\gamma\)/Adiponectin Signalling

Alexios S. Antonopoulos\(^a\), Marios Margaritis\(^a\), Sander Verheule\(^b\), Alice Recalde\(^a\), Fabio Sanna\(^a\), Laura Herdman\(^a\), Costas Psarros\(^a\), Hussein Nasrallah\(^b\), Patricia Coutinho\(^a\), Ioannis Akoumianakis\(^a\), Alison C. Brewer\(^a\), Rana Sayeed\(^d\), George Krasopoulos\(^c\), Mario Petrou\(^c\), Akansha Tarun\(^c\), Dimitris Tousoulis\(^c\), Ajay M. Shah\(^d\), Barbara Casadei\(^a\), Keith M. Channon\(^a\), Charalambos Antoniades\(^a\)

\(^a\)Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom
\(^b\)Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Netherlands
\(^c\)Department of Cardiology, Athens University Medical School, Athens, Greece
\(^d\)Cardiovascular Division, King's College London BHF Centre, London, United Kingdom
\(^e\)Department of Cardiac Surgery, John Radcliffe Hospital, Oxford United Kingdom

1\(^{st}\) Author’s Surname: Antonopoulos
Short title: Epicardial adipose tissue and myocardial redox

Corresponding author
Charalambos Antoniades MD PhD
Associate Professor of Cardiovascular Medicine
Division of Cardiovascular Medicine, University of Oxford
John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Tel: +44-1865-228340, Fax: +44-1865-740352
e-mail: antoniad@well.ox.ac.uk
Detailed Methods

**Blood Sampling and Circulating Biomarkers Measurements**

Venous blood samples were obtained after 8 hours of fasting, at the morning of the operation for measurements of circulating biomarkers. After centrifugation at 2000 g / 4°C for 15 min, plasma or serum was collected and stored at −80 °C until assayed. Whole blood was also collected for genotyping. Serum adiponectin and interleukin 6 (IL-6), a marker of inflammation, were measured using enzyme linked immunosorbent assays (ELISA) (BioVendor, Brno, Czech Republic and R&D systems USA respectively). Plasma malondialdehyde (MDA), a marker of systemic oxidative stress, was quantified by using the TBARS fluorometric assay, as previously described. High sensitivity C-reactive protein (hsCRP), another marker of inflammation, was measured by the high-sensitivity latex enhanced immunoturbidimetric assay (ADVIA, Bayer HealthCare LLC). Plasma BNP was quantified by chemiluminescent-microparticle immunoassay (Architect BNP, Abbott, Germany).

**DNA Extraction and Genotyping**

Genomic DNA was extracted from whole blood using standard methods (QIAamp DNA blood Midi kit, Qiagen). Genotyping for the rs17366568 (functional polymorphism in ADIPOQ gene) and rs266717 SNPs (functional polymorphism in ADIPOQ gene promoter) was performed using TaqMan probes (Applied Biosystems; Assay IDs: C-33187752-10 and C-8288442-10 respectively). The assay was run on an ABI StepOne Plus PCR system according to the manufacturer’s protocol.

**Harvesting of Human Myocardium and Adipose Tissue Samples**

During CABG, myocardial tissue samples were collected from the site of right atrial appendage (RAA) as we have previously described, and transferred into oxygenated (95% O₂ / 5% CO₂) ice-cold buffer. Samples of EpAT were harvested from the site of the right atrioventricular groove (inside the pericardial sac, attached to the heart), while thoracic adipose tissue (ThAT) samples were harvested from outside the pericardium (as “control” samples to the EpAT) and transferred in ice-cold phosphate buffer saline. All tissue samples were transferred immediately to the lab and either used for *ex-vivo* experiments or stored at -80°C for other studies as described below.

**Myocardial Superoxide Measurements**

Myocardial O₂⁻ production was measured in samples of right atrium appendages using lucigenin (5μmol/L)-enhanced chemiluminescence, as we have previously described. Myocardial tissue was homogenised in ice-cold Krebs HEPES Buffer pH 7.35 in the presence of protease inhibitor (Roche Applied Science, Indianapolis, IN) using a pre-cooled Polytron homogeniser. The contribution of NADPH oxidase activity to myocardial O₂⁻ production was quantified in the presence of NADPH 100μmol/L. The use of homogenates allows us to overcome issues regarding penetration of NADPH (which is a polar molecule) into the cells or tissue. In certain *ex vivo* experiments with myocardial tissue, Vas2870 (40 μmol/L, a specific pan NADPH oxidase inhibitor) was also used to get the Vas2870-inhibitable O₂⁻ signal as a more specific index of NADPH oxidase activity. In a pilot experiment comprising 10 RAA samples, we found that VAS2870 inhibitable O₂⁻ (pan-Nox inhibitor) was co-linear to the gp91dstat-inhibitable O₂⁻ (specific for Nox2) with r=0.8875 and P=0.0012. Therefore the use of vas2870 as an NADPH-oxidase inhibitor in the human right atrial appendage provides information mainly on Nox2-derived O₂⁻.

**DHE Staining Method**

In situ O₂⁻ production was determined in right atrial appendage cryosections with the oxidative fluorescent dye dihydroethidium (DHE) as previously described. Briefly, myocardial tissue was washed in ice-cold Krebs HEPES buffer and then cut into thin strips containing all myocardial layers. The tissue was first equilibrated for 20min in Krebs HEPES Buffer pH 7.35 at 37°C and then incubated for 2 hours in the presence or absence of recombinant full-length adiponectin 0.3 μmol/L (10 μg/ml, BioVendor) +/- CC (10 μmol/L). At the end of the incubation period tissue was collected and snap frozen in OCT. Myocardial cryosections (30μm) were equilibrated in Krebs Hepes buffer with or without Vas2870 (40μmol/L) or peg-SOD (300 U/ml). Then the samples were incubated with
DHE (2 μmol/L for 5 minutes). Fluorescence images of the myocardium (x63, Zeiss LSM 510 META laser scanning confocal microscope) were obtained from each myocardial tissue quadrant. In each case, segments of myocardial tissue (with and without Vas2870 or peg-SOD) were analyzed in parallel with identical imaging parameters. DHE fluorescence was quantified by using Image-Pro Plus software (Media Cybernetics), while all analyses were performed in a blinded fashion.

**RNA Isolation and Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR)** Samples of adipose tissue and myocardial tissue samples were snap frozen in QIAzol (Qiagen, Stanford, CA) and stored at -80°C until processed. RNA was extracted by using the RNeasy Micro or Mini kit (Qiagen). RNA was converted into complementary DNA (Quantitect Rev. Transcription kit - Qiagen), then subjected to qPCR using TaqMan probes (Applied Biosystems, Foster City, CA). The reactions were performed in triplicate in 384-well plates, using 5 ng of cDNA per reaction, on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). The efficiency of the reaction in each plate was determined based on the slope of the standard curve; relative expression of ADIPOQ gene was calculated using the Pfaffl method 3.

For the clinical studies, PPIA (cyclophilin) and PGK1 were used as housekeeping genes for adipose tissue and myocardial tissue, respectively. The Assay IDs of the Taqman probes used were ADIPOQ (adiponectin gene): Hs00605917_m1, ADIPOR1: Hs01114951_m1, ADIPOR2: Hs00226105_m1, CDH13: Hs01004530_m1, CD36: Hs01567185_m1, PPARG: Hs01115513_m1, PGK1: Hs00943178_g1, PPIA: Hs04194521_s1, CYBB(NOX2), NOX4, CYBA (P22PHOX), NCF1 (P47PHOX), NCF2 (P67PHOX).

For the rat epicardial adipose tissue (see below), PPIA was used as housekeeping gene. The Assay IDs of the Taqman probes used were PPIA: Rn00690933_m1, ADIPOQ: Rn00595250_m1, PPARG: Rn00440945_m1, CD36: Rn00560963_s1.

For the mouse model (see below), PPIA and actin-alpha (ACTA) were used as housekeeping genes for adipose tissue and myocardial tissue, respectively. The Assay IDs of the Taqman probes used were ACTA: Mm00808218_g1, ADIPOQ: Mm00456425_m1, ADIPOR1: Mm01291334_mH, ADIPOR2: Mm01184032_m1, CDH13: Mm00490584_m1, PPIA: Mm02342429_g1.

For the pig model, PPIA and actin-beta (ACTB) were used as housekeeping genes for adipose tissue and myocardial tissue, respectively. The assay IDs of the Taqman probes used were ACTB: Ss03376160_u1, ADIPOQ: Ss03384375_u1, ADIPOR1: Ss03778803_u1, ADIPOR2: Ss03391825_g1, CDH13: Ss03386756_u1, PPIA: Ss03394782_g1.

**Western Blots in human myocardial samples**

To investigate adiponectin-AMPK signaling axis and its effects on NADPH oxidase activity, western immunoblotting was used to examine the direct effects of adiponectin on phospho(Th172)-AMPKα, total AMPKα, phospho(Ser473)-Akt, pan-Akt, phospho(Ser79)-acetyl-CoA carboxylase (ACC) and total ACC (antibodies by Cell Signaling, Danvers, MA), Nox1, Nox2 (antibodies by BD Transduction Laboratories), Nox4, Nox5 (antibodies by Abcam, Cambridge, UK), phospho(Ser359)-p47phox, total p47phox, p67phox (antibodies by Cell Signaling), and total Rac1 (antibody by Merck Millipore, Billerica, MA) protein levels in human myocardium incubated ex vivo. Selected myocardial tissue samples from Clinical Associations Studies were also used to evaluate the content of 4-hydroxynonenal (4HNE) and malonyldialdehyde (MDA) adducts, the two most common lipid oxidation products (formed when reactive oxygen species react with lipid membranes, antibodies by Abcam) in the presence of high or low myocardial NADPH-stimulated O2− generation. Briefly, myocardial tissue samples were homogenized for 30 seconds using a pre-cooled electric Polytron homogenizer in 300 μl of lysis buffer (Invitrogen, UK) containing a protease and phosphatase inhibitor cocktail (Roche Applied Science). Homogenates were spun at 13,000 rpm for 10 minutes, at 4°C. The protein concentration of the supernatants was then measured using the BCATM Protein Assay kit (Pierce, UK). Protein lysates were separated on 4-12% gradient SDS-NuPAGE gel (Invitrogen, UK), and proteins transferred to polyvinylidene difluoride membranes (Amersham, UK Ltd.), followed by blocking with 5% powdered skimmed milk. The membranes were incubated with the respective primary antibodies overnight and immunodetection of the primary antibodies was performed with horseradish-peroxidase-conjugated secondary antibodies (Promega) and enhanced
chemiluminescence (Amersham Bioscience UK Ltd.) and quantified in relation to the house-keeping protein, GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA).

Measurement of Myocardial Rac1 Activation and Membrane Translocation Experiments
Rac1 activation was evaluated by a commercially available affinity precipitation assay using the PAK1-PBD conjugated glutathione agarose beads (Millipore, Temecula, USA). To estimate membrane translocation of Rac1 and p47phox, we performed differential centrifugation for isolation of membrane proteins, and membrane-translocated Rac-1 and p47phox proteins were determined by Western immunoblotting as previously described.

Measurement of intracellular NADP/NADPH levels
For measurements of intracellular NADP/NADPH levels, a commercially available fluorometric assay was used (Abcam kit, Cambridge, UK). Following the 18 hour treatment, H9C2 cells were washed 3x with PBS and then lysed. Twenty five μl of the lysates were loaded into a black walled 96-well plate for processing. Finally, 75ul of NADPH reaction mixture was added to initiate the reaction according to manufacturer’s instructions and after 45 minutes the fluorescence was measured at Ex/Em=540/590nm. The assay kit provides measurements of intracellular NADPH, NADP and total NADPH/NADP separately.

Animal studies
Generating the mouse model: The cardiomyocyte-specific NOX2 overexpressing mouse model (mNOX2-tg) was generated in the laboratory of Ajay Shah. The expression of the human 1.8kb NOX2 cDNA was driven by the mouse myosin light chain-2 (MLC-2v) promoter. Transgenic founders were backcrossed for >10 generations onto a C57BL/6 background.

The decision to overexpress human NOX2 in these mice was based on our findings in Clinical Associations Studies in which NOX2 gene expression was strongly correlated with myocardial O2− in the human right atrium appendages (Online Figure X), while its activation dependents on p47phox phosphorylation/membrane translocation and Rac1 activation. On the other hand, unlike Nox2, Nox4 does not require Rac1/p47phox membrane translocation to be activated, and exploring its role in this setting was beyond the scope of the current study.

Pig model: In 10 Dutch Landrace pigs (62±3 kg), anesthesia was induced with Zoletil (5-8mg/kg i.m.) and Thiopenthal (5-15mg/kg i.v.). After intubation, anesthesia was maintained by intravenous infusion of Midazolam (1.0mg/kg/h), Sufentanyl (4mg/kg/h) and Propofol (2.5-10mg/kg/h). An endocardial lead (Capsurefix 5568, Medtronic, Minneapolis, MN) was implanted in the right atrium and connected to a subcutaneous pacemaker (Itrel II, Medtronic, Minneapolis, MN). Healthy pigs (61±2 kg) served as a control group. After one week recovery, the pacemaker was switched on at a rate of 10Hz for 5 weeks. The ventricular rate was controlled by digoxin 10μg/kg for 1 week, followed by 5μg/kg for 4 weeks. Digoxin was discontinued 3 days before the sacrifice experiment in order to reach plasma levels <0.5μg/ml. At sacrifice, animals were anesthetized as described above and the heart was excised via a left lateral incision. Epicardial adipose tissue was collected from the posterior left atrium, close to the AV ring. For comparison, subcutaneous fat was taken from the incision in the thorax.

Power calculations
Sample size calculations were based on previous data from our laboratory. For the clinical studies, we estimated that a total number of 200 subjects would allow us to detect a 0.31 (or 7.5%) difference in log(mycardial NADPH-stimulated O2−) between the extreme tertiles of plasma adiponectin with an α=0.05, a power of 0.9, and an assumed standard deviation of 0.57. For the ex vivo experiments, sample size calculations were performed on the basis of pilot experiments and we estimated that with a minimum of 5 pairs of samples (serial samples from the same myocardial tissue), we would be able to identify a change in log(mycardial NADPH-stimulated O2−) of 0.84 (or 20%) with an α=0.05, a power 0.9, and a standard deviation for a difference in the response of the pairs of 0.44. Power calculations for the animal experiments were based on pilot data on adiponectin expression from epicardial adipose tissue; for the transgenic mice experiments, we estimated that with a minimum of 5 mice per group, we would be able to identify a change in adiponectin gene expression of 0.51 (2fold
change) with an $\alpha=0.05$, a power 0.9, and a standard deviation for a difference in the response of the pairs of 0.22. Similarly, for the pig model of atrial pacing, we estimated that with a minimum of 5 pigs per group, we would be able to identify a change in adiponectin gene expression from epicardial adipose tissue of 0.91 (3fold change) with an $\alpha=0.05$, a power 0.9, and a standard deviation for a difference in the response of the pairs of 0.39.
**Supplemental Tables**

**Online Table I:** Multivariable models of myocardial NADPH-stimulated O$_2^-$ and serum adiponectin

### Model for myocardial NADPH-stimulated O$_2^-$

**Univariate analysis**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Correlation coefficient*</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log(serum adiponectin)</td>
<td>0.361</td>
<td>0.0001</td>
</tr>
<tr>
<td>Log(plasma BNP)</td>
<td>-0.045</td>
<td>0.601</td>
</tr>
<tr>
<td>Age</td>
<td>0.179</td>
<td>0.031</td>
</tr>
<tr>
<td>Male gender</td>
<td>-0.220</td>
<td>0.007</td>
</tr>
<tr>
<td>Smoking status</td>
<td>0.153</td>
<td>0.064</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>-0.213</td>
<td>0.023</td>
</tr>
</tbody>
</table>

**Multivariable analysis (R$^2$ for the model: 0.211, P=0.001)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Standardized beta</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log(serum adiponectin)</td>
<td>3.802</td>
<td>0.001</td>
</tr>
<tr>
<td>Log(plasma BNP)</td>
<td>-0.08</td>
<td>0.465</td>
</tr>
<tr>
<td>Age</td>
<td>0.063</td>
<td>0.526</td>
</tr>
<tr>
<td>Male gender</td>
<td>-0.086</td>
<td>0.419</td>
</tr>
<tr>
<td>Smoking status</td>
<td>0.034</td>
<td>0.734</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>-0.163</td>
<td>0.137</td>
</tr>
</tbody>
</table>

### Model for circulating adiponectin

**Univariate analysis**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Correlation coefficient*</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log(NADPH stimulated O$_2^-$)</td>
<td>0.361</td>
<td>0.0001</td>
</tr>
<tr>
<td>Log(plasma BNP)</td>
<td>0.257</td>
<td>0.0001</td>
</tr>
<tr>
<td>Male gender</td>
<td>-0.175</td>
<td>0.008</td>
</tr>
<tr>
<td>Age</td>
<td>0.224</td>
<td>0.001</td>
</tr>
<tr>
<td>Body mass index</td>
<td>-0.126</td>
<td>0.07</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>-0.128</td>
<td>0.05</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>-0.175</td>
<td>0.009</td>
</tr>
</tbody>
</table>

**Multivariable analysis (R$^2$ for the model: 0.215, P=0.0001)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Standardized beta</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log(NADPH stimulated O$_2^-$)</td>
<td>0.210</td>
<td>0.016</td>
</tr>
<tr>
<td>Log(plasma BNP)</td>
<td>0.229</td>
<td>0.008</td>
</tr>
<tr>
<td>Male gender</td>
<td>-0.210</td>
<td>0.017</td>
</tr>
<tr>
<td>Age</td>
<td>-0.042</td>
<td>0.082</td>
</tr>
<tr>
<td>Body mass index</td>
<td>-0.148</td>
<td>0.225</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>-0.067</td>
<td>0.423</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>-0.102</td>
<td>0.628</td>
</tr>
</tbody>
</table>

BNP: Brain natriuretic peptide; *Spearman’s or Pearson’s correlation coefficient as appropriate
Supplemental Figures and Figure Legends

Online Figure I

Obesity and adiponectin/PPAR-γ gene expression in thoracic and epicardial adipose tissue. In patients of Clinical Associations Studies (clinical cohort of 247 patients undergoing coronary artery bypass grafting), there was a significant inverse association between increased body mass index (BMI) and adiponectin gene (ADIPOQ) expression from thoracic adipose tissue (AT, Panel A). A trend towards lower PPAR-γ gene expression from thoracic AT with increased BMI was observed too but this did not reach statistical significance (Panel B). Abdominal obesity as assessed by the waist to hip ratio was also associated with lower ADIPOQ (Panel C) and PPAR-γ gene expression (Panel D) from thoracic AT. On the other hand, BMI and waist to hip ratio were not associated with adiponectin (Panel E & G) or PPAR-γ gene expression (Panel F & H) in epicardial AT. p-values are derived from ANOVA.
Effects of recombinant adiponectin on the expression of NADPH oxidase subunits and protein kinase C-α phosphorylation. Human myocardium was incubated ex-vivo for 2h in the presence or absence of recombinant human adiponectin (10μg/mL). Adiponectin did not lead to a significant increase in activity of Akt in this tissue, as assessed by Western blotting for phospho-Ser473 Akt, even though a positive trend was observed (Panel A). There was also no effect of adiponectin on the phosphorylation of protein kinase C-α at Thr497 (PKCα, Panel B), suggesting that its effects on NADPH oxidase were independent of any effects on Akt or PKCα signalling. Moreover, adiponectin did not have any effects on the protein levels of Nox2 and Nox4 isoforms or the protein levels of NADPH oxidase subunits, namely p22phox, p47phox and p67phox (Panel C-D). n=10-12 for the adiponectin group and n=5-7 for the compound C; NS vs control group.
Changes of intracellular NADP/NADPH levels after incubation with exogenous NADPH. H9C2 cells were incubated with / without NADPH 100μmol/L for 18h, in conditions that mimic the co-culture experiments. Then the cells were washed thoroughly and lysed to measure intracellular concentration of NADPH, NADP and total NADP/NADPH using a fluorometric assay. There was a significant increase of both NADPH (by ~25%, A) and NADP (by ~25%, B), with the total NADP/NADPH being increased by ~45% (C) compared to control (**P<0.001 vs control). N=6 independent experiments.
Online Figure IV

Co-culture of rat epicardial adipose tissue and H9C2 cells pre-stimulated with PMA. To examine whether under conditions of increased endogenous oxidative stress cardiomyocytes release a transferable factor able to affect the activation of PPAR-γ/adiponectin signalling in rat epicardial adipose tissue (EpAT), we exposed H9c2 cells to Phorbol-12-Myristate-13-Aacetate (PMA, 160 nmol/L) while rat EpAT was conditioned ex vivo (Panel A). After 2h, the rat EpAT was transferred into the H9c2 wells and co-cultured for an additional 16 hours (Panel A). At the end of the incubation period, gene expression of PPAR-γ and ADIPOQ were studied in the rat EpAT. Addition of PMA to intact H9c2 cells grown on coverslips led to a striking increase of NADPH oxidases-derived superoxide (O₂⁻, Panel B), as demonstrated by real-time monitoring using lucigenin-enhanced chemiluminescence. Co-incubation of rat EpAT with H9c2 cardiomyocytes stimulated with PMA resulted in an up-regulation of ADIPOQ (Panel C) and PPAR-γ expression (Panel D) in EpAT at 16h. These effects were prevented by VAS2870 (10nmol/L). However, PMA alone had a similar direct effect on ADIPOQ and PPAR-γ expression in EpAT even in the absence of H9C2 cells. DMEM: Dulbecco’s Modified Eagle Medium; n=7 independent experiments; *p<0.05 vs control group.
Short-term NADPH stimulation of human myocardium increases the formation of 4-HNE adducts. Human myocardium from patients undergoing coronary artery bypass grafting operation was incubated ex vivo for 16h +/- NADPH 100μmol/L (as a means to induce superoxide generation from NADPH oxidase). This interaction resulted in increased formation of 4-hydroxynonenal protein adducts (by-products of lipid oxidation) in myocardial tissue (Panel A). n=5 independent experiments; *p<0.05 vs control group.
**Online Figure VI**

**Ex vivo incubations of human epicardial adipose tissue with H\textsubscript{2}O\textsubscript{2}.** Exposure of human epicardial adipose tissue (EAT) to H\textsubscript{2}O\textsubscript{2} (100 μmol/L) for 16 h led to a significant reduction in adiponectin (ADIPOQ) gene expression, with no significant changes in PPAR\textgamma or CD36 expression (n=8 independent experiments, *p<0.05 vs control).
Ex-vivo incubation of epicardial (EpAT) and thoracic (ThAT) adipose tissue with malonyldialdehyde (MDA). EpAT and ThAT from 6 patients undergoing coronary artery bypass grafting was incubated ex-vivo for 16 hours in the presence or absence of MDA 1mM and used for gene expression studies. MDA did not have any effects on the relative expression levels of PPAR-γ and CD36 gene in either EpAT (Panels A-B) or ThAT (Panels C-D). n=5-6 independent experiments; NS: non significant vs control group.
Comparison of peroxisome proliferator activated receptor-γ (PPAR-γ) expression and activation between human adipose tissue depots. Adipose tissue samples of patients with coronary artery disease, were used to compare the expression of PPAR-γ and its downstream mediator CD36 in epicardial (EpAT) vs thoracic adipose tissue (ThAT). Both the expression of PPAR-γ (A) and its downstream molecule CD36 (B) were higher in EpAT compared to ThAT.
Mouse model of cardiomyocyte-specific overexpression of human NOX2. There was no difference in the expression of murine NOX2 in the heart of mNOX2-tg vs the wild type (wt) animals (Panel A). On the contrary, mNOX2-tg mice were over-expressing human NOX2 in their cardiomyocytes, which was not expressed in the wt mice (Panel B). n=9-10 per group; NS: non-significant; ****p<0.0001 vs wt.
Online Figure X

**NOX2 expression and** $O_2^-$ **generation in the human right atrium appendages (RAA).** High NOX2 gene expression in human RAA was significantly associated with increased resting $O_2^-$ (A), NADPH-stimulated $O_2^-$ (B) and Vas2870-inhibitable $O_2^-$ (C) in the same tissue.
Schematic representation of the bi-directional signalling between epicardial adipose tissue and the myocardium. The cross-talk between epicardial adipose tissue (EpAT) and the myocardium involves the release of oxidation products from the heart (4-hydroxynonenal- 4HNE) able to trigger peroxisome proliferator activated receptor (PPAR)-γ – induced expression of adiponectin (AdN) in EpAT, which may suppress NADPH oxidases activity in the underlying heart muscle in a paracrine way, via an AMPK (AMP kinase) –dependent activation of Rac1 and phosphorylation of p47phox subunits of NADPH oxidase. AT: Adipose Tissue.
Supplemental References


